Last reviewed · How we verify

Zilovertamab vedotin — Competitive Intelligence Brief

Zilovertamab vedotin (Zilovertamab vedotin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody-drug conjugate. Area: Oncology.

phase 3 Monoclonal antibody-drug conjugate CD30 Oncology Biologic Live · refreshed every 30 min

Target snapshot

Zilovertamab vedotin (Zilovertamab vedotin) — Merck Sharp & Dohme LLC. Zilovertamab vedotin is a monoclonal antibody-drug conjugate that targets the CD30 antigen.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Zilovertamab vedotin TARGET Zilovertamab vedotin Merck Sharp & Dohme LLC phase 3 Monoclonal antibody-drug conjugate CD30
Brentuximab Vedotin (Bv) Brentuximab Vedotin (Bv) Assistance Publique - Hôpitaux de Paris marketed Antibody-drug conjugate (ADC) CD30
enfortumab vedotin (EV) enfortumab vedotin (EV) Astellas Pharma Global Development, Inc. phase 3 Monoclonal antibody-drug conjugate Nectin-4
gemtuzumab ozogamycin gemtuzumab ozogamycin Nantes University Hospital phase 3 Monoclonal antibody-drug conjugate (ADC) CD33

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody-drug conjugate class)

  1. GlaxoSmithKline · 2 drugs in this class
  2. RemeGen Co., Ltd. · 2 drugs in this class
  3. Copharos · 1 drug in this class
  4. Eastern Cooperative Oncology Group · 1 drug in this class
  5. Merck Sharp & Dohme LLC · 1 drug in this class
  6. Mirati Therapeutics Inc. · 1 drug in this class
  7. NYU Langone Health · 1 drug in this class
  8. The Lymphoma Academic Research Organisation · 1 drug in this class
  9. Astellas Pharma Global Development, Inc. · 1 drug in this class
  10. Yan Zhang, MD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Zilovertamab vedotin — Competitive Intelligence Brief. https://druglandscape.com/ci/zilovertamab-vedotin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: